Dr Sinisa Dovat talks to ecancer at the European School of Haematology (ESH) meeting: International Conference on Acute Lymphoblastic Leukaemia about the epigenetic regulation in T-cell leukaemia.
He explains how the function of the tumour suppressor, IKZF1/Ikarus, its role in leukaemia and how these can be a target for therapy.
Dr Dovat discusses the next steps for this research, which include examining epigenetic expression using human B cells and T cells and a phase I trial for these haematologic malignancies.
ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.